Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide Efficacy in Pediatric Short Bowel Syndrome Using Human Intestinal Organoids
NCT07400783Recruiting
- Sponsor
- Meyer Children's Hospital IRCCS
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of teduglutide in short bowel syndrome (SBS) (2 arms), sponsored by Meyer Children's Hospital IRCCS. Primary endpoints: Intestinal organoid diameter at 7 days, Crypt-villus-like architecture in intestinal organoids at 7 days and 4 more. Started Oct 2024; status: recruiting.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT07400783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400783.